Clinical Trial Update: A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide [Phase 2]

View source ↗

Summary

Phase 2 ARAMON study comparing darolutamide with enzalutamide to evaluate the effect on testosterone levels in men with biochemically recurrent prostate cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biochemically Recurrent Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)
• Xtandi (enzalutamide)

Snippet

Sponsor: Bayer | Conditions: Biochemically Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-10-15